The corticotropin releasing factor (CRF) peptide hormone family members coordinate endocrine, behavioral, autonomic and metabolic responses to stress and play important roles within the cardiovascular, gastrointestinal and central nervous systems, among others. The actions of the peptides are mediated by activation of two G-protein coupled receptors (GPCRs) of the B1 family, CRF receptors 1 and 2 (CRF-R1 and CRF-R2α,β ). The recently reported 3D structures of the first extracellular domain (ECD1) of both CRF-R1 and CRF-R2β (1,2) complexed with peptide antagonists provided a starting point in understanding the binding between CRF ligands and receptors at a molecular level. We now report the 3D NMR structure of the ECD1 of human CRF-R1 complexed with a high affinity agonist, αhcCRF. In the structure of the complex, the C-terminal residues (23-41) of αhcCRF bind to the ECD1 of CRF-R1 in a helical conformation mainly along the peptide's hydrophobic face in a manner similar to that of the antagonists in their corresponding ECD1-complex structures. Unique to this study is the observation that complex formation between an agonist and the ECD1-CRF-R1 promotes the helical conformation of the N-terminus of the former, important for receptor activation (3,4
for receptor signaling as long as α-helicity is maintained (3, 4, (16) (17) (18) . On the other hand, the C-terminal (~15) residues contribute significantly to receptor binding affinities (16, 19) . Similar data, both on signaling and binding properties, have been reported for the other members of the B1 GPCR family and their corresponding ligands (20) (21) (22) (23) (24) .
Recently, 3D structures of the ECD1's of several B1 family receptors in the presence and absence of their respective ligands have been solved. The structures reported include the NMR structure of the mouse CRF-R2β free and complexed with the CRF antagonist astressin (2), the NMR structure of the human splice variant PAC1-R s complexed with the Nterminally truncated antagonist PACAP(6-38) (25) , the crystal structure of human GIP-R complexed with its agonist incretin GIP(1-42) (26) , the crystal structure of the human GLP-1R complexed with the antagonist exendin-4(9-39) (27) , the crystal structure of human PTH-1R fused to maltose-binding protein (MBP) complexed with the peptide fragment PTH(15-34) (28) and the crystal structure of the human CRF-R1 fused to MBP complexed with CRF antagonists (1) (Fig. 1 ). These structures show that the short consensus-repeat (SCR) is the common polypeptide fold for the receptors' ECD1s (29) , and the interaction of the Cterminal part of their cognate ligands is along the hydrophobic face of their helices.
Here, we report the 3D NMR structure of the human ECD1-CRF-R1 (14) complexed with the peptide agonist α-helical cyclic CRF (αhcCRF). The motivation for these studies is the identification of the binding surface involved in the recognition of a high affinity agonist, the subsequent comparison with that previously reported for the antagonists and the determination of reciprocal conformational changes in both the receptor and the agonist.
MATERIALS AND METHODS

Protein expression and purification
The purification and labeling of the ECD1-CRF-R1 expressed in E.coli was carried out as described in (15, 29) .
Synthesis of αhcCRF, with C-13 and N-15 isotopically labeled amino acids
The synthesis was performed on a methyl-benzhydrylamine resin using the Fmoc strategy. Purification and characterization used established procedures (see (30, 31) ). Full details are given in the Supplemental Information section.
Radioreceptor assays Radioreceptor assays for full-length receptors expressed in mammalian cells were carried out as described in (14) and for soluble receptors as described in (32) .
NMR Experiments and Analysis
All NMR spectra were recorded at 35 ºC using a Bruker 700 MHz spectrometer equipped with four radio-frequency channels and a triple resonance cryo-probe with shielded z-gradient coil. The NMR samples contained either 0.3 mM 13 C, 15 Nlabeled ECD1-CRF-R1 and an equimolar concentration of unlabeled αhcCRF or 0.3 mM 13 C, 15 N-labeled αhcCRF (labeled uniformly by 15 (39) spectra recorded with mixing times of either 100 or 120 ms. All of the spectra quadrature detection in the indirect dimensions was achieved using States-TPPI (40) . The water signal was suppressed using spin-lock pulses (41) or the WATERGATE sequence (42) . All of the spectra were processed with the program PROSA (43) and were analyzed with the program CARA (44) .
Determination of the structure of ECD1-CRF-R1 complexed with αhcCRF Meaningful distance restraints (ca. 1718) and angle restraints (371) were collected for the calculation of the structure of the complex (Table 1) . These structural restraints were used as an input for the structure calculation with the program CYANA (43) followed by restrained energy minimization using CNS (45). A total of 100 conformers were initially generated by CYANA, and the bundle of 20 conformers with the lowest target function was used to represent the 3D NMR structure. The structures are validated with the program PROCHECK (46) and the structure has been deposited in the protein data bank database with ID code XXXX.
RESULTS
Selection of a soluble high-affinity agonist
A major challenge in the 3D structure determination of ECD1-CRF-R1 complexed with an agonist was to obtain a high affinity agonist that was soluble above pH 5 at concentrations required for the NMR experiments. Comparison of several CRF analogs showed that the novel CRF agonist, αhcCRF, satisfied the requirements i.e., it bound with low nanomolar affinity to both CRF-R1 (~1 nM) and the ECD1-CRF-R1 (~30 nM, Table 2 ) and was soluble at physiological pH. This peptide is only, in part, related to α-helical-CRF(1-41) and to astressin (3, 47 Fig. 2A) . Changes in pH or temperature failed to improve the quality of the spectrum. The absence of these peaks in the spectrum may be due to slow conformational exchange dynamics involving the backbone, which results in line broadening so severe that peaks cannot be detected. A similar observation was documented for the free ECD1-CRF-R2β, but was limited to only a few residues located in loop 2 [i.e., Y87 (corresponding to F71 in CRF-R1), F88 (F72); N89 (Y73), G90 (G74), I91 (V75), K92 (R76), R97 (N81)] (2). For the ECD1-CRF-R2β, this slow conformational exchange was estimated to be on the time scale of 10 -2 seconds and a similar rate is also estimated for the ECD1-CRF-R1. However, since the number of cross peaks absent in the [ 15 N, 1 H]-TROSY spectrum is much larger for ECD1-CRF-R1 than for ECD1-CRF-R2β, the conformational exchange dynamics of ECD1-CRF-R1 must be of greater amplitude and/or must involve a larger segment of the ECD1-CRF-R1 compared to ECD1-CRF-R2β. For ECD1-CRF-R2β, this slow conformational exchange phenomenon was suppressed, at least in part, when complexed with the antagonist astressin, since all of the missing cross peaks of the amide moieties appeared in the [ 15 N, 1 H]-TROSY spectrum of the complex. Assuming that all of the peaks might appear in the spectrum of ECD1-CRF-R1 complexed with the agonist, we carried out the structural studies of the ECD1-CRF-R1 complexed with αhcCRF.
Mapping the agonist binding site on ECD1-CRF-R1 by agonist-induced chemical shift changes Insight into the agonist binding site on ECD1-CRF-R1 can be obtained from an analysis of the resonance shifts in the NMR spectra upon addition of αhcCRF (34). Fig. 2A 2C ). This structural study, together with similar chemical shift perturbation data observed for the ECD1-CRF-R2β-astressin complex (2), suggest that both the agonist and antagonist interact with the same residues in the ECD1s.
3D structure of the ECD1-CRF-R1 complexed with αhcCRF Almost complete sequential assignment of the various resonances of the ECD1-CRF-R1-αhcCRF complex was obtained using standard procedures and the 3D structure was determined (see Materials and Methods). The good quality of the 3D structure is represented by the small root mean square deviation (r.m.s.d.) of 0.88 Å for residues 42-105 of the ECD1 and for residues 27-38 of αhcCRF ( Fig. 3A and 3B ), as well as by the small value of residual constraint violations in the 20 refined conformers, and by the small deviations from ideal geometry ( Table 1 ). In addition, the input data represent a selfconsistent set, the restraints are well satisfied in the calculated conformers, and similar energy values were obtained for all of the 20 conformers.
As documented already in the structures of the ECD1 of CRF-R2β (2,29) and of the ECD1s of the other members of the B1 receptor family (25) (26) (27) (28) , the overall fold of the ECD1 of CRF-R1 is the short consensus repeat (SCR) motif with the three disulphide bonds between cysteine residues, C 30 (i) the larger dispersion of the cross peaks attributed to a higher ordered structure of αhcCRF in the complex, and (ii) broad cross peaks with large line-widths due to the larger size of the complex and/or due to slow conformational exchange. Most prominent chemical shift changes as well as line broadening are observed for the C-terminal residues of αhcCRF with the maximum shift for A 41 (Fig. 4E) . The chemical shifts for the C α , C β and H α protons (Fig. 4C and 4D , black bars) suggest that αhcCRF prefers a helical conformation when bound to the ECD1-CRF-R1 and that the helicity is more pronounced upon complex formation not only at the C-terminus but also towards the N-terminus of the peptide (Figs. 4A and 4B 4F) show a wave-like pattern attributed to the amphipathic nature of the helix in the complex, observed also for astressin bound to the ECD1 of CRF-R2β (2). In addition, a kink of the long helix is observed between residues E 27 to E 29 of αhcCRF (Fig. 3) . The positioning of this kink is similar to the kinks observed for CRF family ligands in the solvent DMSO (48) but is absent in all the other ligands of family B1 when they are bound to their respective ECD1s in the crystal structures. Although the role of this kink may be understood only in the context of the full-length receptor, it enlarges the conformational space of the N-terminal peptide segment which is possibly important for receptor-specific signaling (Fig. 3A) (49, 50) .
Molecular interactions between αhcCRF and the ECD1
The helical segment of αhcCRF bound to the ECD1 is along the protein's hydrophobic face, covering an area of 2647 Å 2 of the ECD1 (Fig. 5) are indicative of its interactions with aromatic side chains of the ECD1). The amide group at the C-terminus of αhcCRF is involved in an inter-molecular hydrogen bond with the backbone carbonyl of V 97 . In return, the backbone amide proton of V 97 is involved in a hydrogen bond with the backbone carbonyl of A 41 in αhcCRF (Fig. 5) . These hydrogen bonds explain the necessity of C-terminal amidation for high affinity recognition of CRF ligands (48, 51 
DISCUSSION
Comparison of the structures of ECD1-CRF-R1
complexed with the agonist αhcCRF and ECD1-CRF-R2β complexed with the antagonist astressin Recently, our group reported the structure of the ECD1 of CRF-R2β complexed with the peptide antagonist astressin (2) . Comparison of the structures of the complexes of ECD1-CRF-R1 and ECD1-CRF-R2β enables the identification of the common interaction sites. Both of the structures have the SCR motif characteristic of the ECD1s of family B1 members (Fig. 6A ). There is a short N-terminal helix observed for ECD1-CRF1-R1, which was absent in the structure of ECD1-CRF-R2β because in the latter, the N-terminal segment was truncated in the protein construct. While conformation of loop 1 is not defined in either ECD1, loops 2 and 3 are structured and interact with the corresponding ligand in a slightly different manner (Fig. 6B) . The backbone of loop 2 of ECD1-CRF-R2β folds closer to the ligand than the corresponding loop in ECD1-CRF-R1, while the opposite holds for loop 3.
There are also structural differences of the ligand. Although both the agonist and the antagonist bind to almost the same region of the ECD1, the orientations of the ligands are slightly different with respect to loop 2 (Fig. 6B, C, D) . Furthermore, the C-terminal residues of astressin prefer a 3 10 -helix, whereas in αhcCRF, they are in an α-helical conformation. In both ligands, the backbone carbonyl of the last residue (A/I 41 50 for sauvagine and urocortin1 stimulated intracellular cAMP accumulation (data not shown). The side chain of N 34 of astressin is in close proximity to the ECD1 to form a hydrogen bond with the backbone carbonyl of F 88 in ECD1-CRF-R2β. Such a hydrogen bond is missing in the structure of the ECD1-CRF-R1 in complex with αhcCRF. The residues V 75 /I 91 are in almost the same position and they interact with A 31 of the ligand. The side chain of R 35 does not directly interact with E 104 of the ECD1-CRF-R1, although it is close enough to form a solvent-exposed intermolecular salt bridge. In contrast, in ECD1-CRF-R2β, R 35 is involved in a buried salt bridge with E 86 , which, in ECD1-CRF-R1, is replaced by A 70 and its side chain is solvent exposed.
Comparison of the NMR structure of ECD1-CRF-R1-αhcCRF complex and X-ray crystallographic structures of ECD1-CRF-R1 peptide complexes
The NMR structure of ECD1-CRF-R1 complexed with the highaffinity agonist αhcCRF may be compared with the crystal structures of ECD1-CRF-R1 complexed with the low affinity fragments CRF (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) and CRF (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) which are presumed to be antagonists (1) . Interestingly, the ECD1 of CRF-R1 was crystallized in a ligand-dependent manner in three different forms that differ mainly in the conformations of loop 2, to which the ligand binds (Fig. 7) . Pioszak et al. suggest that crystal form II is possibly more relevant, physiologically, than the others since only in crystal form II is loop 2 unhindered from crystal packing constraints (1). Indeed, our NMR structure of ECD-CRF-R1-αhcCRF (Figs. 7E and 7F ) is more similar to the crystal form II than to forms I and III (Figs. 7A  and 7B, 7C and 7D, (1) ). The differences between the NMR and X-ray structures are discussed in detail in Supplemental Information. The comparison between all of the four structures suggests the presence of a structural plasticity of the SCR motif of the ECD1-CRF-R1 (see below). (Fig. 4) . The presence of slow conformational exchange dynamics in the millisecond time range for segments of both the ECD1 and the ligand is in agreement with the presence of conformational heterogeneity observed in both the NMR and Xray structures. Furthermore, the nanomolar binding affinity of the antagonist astressin for a CRF-R2β mutant whose corresponding ECD1 shows molten globule-like conformational states (52) supports the dynamic character of the ECD1. Although we can only speculate about the biological role of these conformational exchange dynamics, their presence could account for the multiple recognition, binding and signaling observed for the various hormone ligands.
Structural plasticity of both the ECD1 and the ligand
Refinement of the two step binding mechanism of CRF peptides to its receptors
The two-step model for ligand-binding and signaling of type B1 GPCRs (29, 53, 54) proposes that the Cterminal segment of the ligand binds to the ECD1, which then may position the aminoterminal portion of the peptide hormone in close proximity to the serpentine regions of the receptor to initiate signaling. The ECD1 is therefore the major peptide-binding domain and conversely, the C-terminal segment of the ligand is important for high binding affinity and selectivity to the receptors. All of the 3D structures of the ECD1-receptor-ligand complexes are consistent with this model, since the C-terminal segment of the peptide ligand interacts with the ECD1 (1,2,26-28). Our NMR studies of the complex between ECD1-CRF-R1 and an agonist further indicate that the recognition of the ligand by the ECD1 not only binds the hormone and positions its N-terminal residues for signal activation, but also induces helix formation towards the N-terminus of the ligand to generate a conformationally active state. In a recent review (55) , this additional function in receptor activation of the ECD1 in family B1 GPCRs was proposed to be based on (i) a structural comparison between various hormone ligands, free and complexed with ECD1s and, (ii) the importance of helix-capping residues in the N-terminal region of the numerous corresponding ligands (56) (57) (58) . The induction of the helix in the ligand upon complex formation with the ECD1 is accompanied by a kink between residues E 24 to E 26 of αhcCRF ( Fig. 3A; Fig. 8) ; this kink may also play a role in receptor activation by either enlarging the conformational space of the Nterminal peptide segment or by positioning the ECD1 relative to the serpentine region of the receptor important for signaling or/and coreceptor interactions (29) . Hence, our 3D structure of the ECD1 of CRF-R1 complexed with an agonist suggests a refined two-step model for receptor activation.
Agonist versus antagonist Previous studies on chemically modified and truncated CRF ligands showed that the first seven residues at the Ntermini of CRF are not necessary for GPCR signaling (3, 4) and that residue 8 was critical, whereas the C-terminal (~15) residues are important for binding (47, 53, 54) . Hence, CRF analogs truncated by 8 residues or more at the N-terminus are antagonists. This finding can easily be understood with the help of the twostep model for ligand binding and signaling of type B1 GPCR discussed above (16, 19, 29) . If the N-terminal segment of the ligand is missing, the C-terminal fragment still binds to the receptor but is not able to produce activation. Such a ligand is then evidently an antagonist since it occupies the major binding site thereby blocking peptide agonist binding. The 3D structure of the ECD1-CRF-R1 complexed with the agonist αhcCRF presented here is the first direct experimental proof that supports this hypothesis (Figs. 7 and 8 ) and shows clearly the similarity of the C-terminal binding of the peptide agonists and antagonists.
CONCLUSION
The information gained from our structural studies complements earlier knowledge of the molecular interactions between ligands and GPCRs of the B1 family. Specifically, the 3D NMR structure presented here of ECD1-CRF-R1 complexed with a high affinity CRF agonist, has identified the residues in the ECD1-CRF-R1 involved in ligand recognition and has highlighted the similarity between agonist and antagonist binding receptor domains. Further, the structure of the complex revealed the extended helicity of the N-terminal domain of the agonist. These data provide further support for the model of ligand-induced receptor signaling in the B1 receptor family. (25) is not included in this figure because they are completely different from that of the other ligands. Whether this difference is an artifact of the procedure used in structure determination or a true difference needs to be determined, . The backbone ribbon of the ECD1 along with the highly conserved residues including the disulphide bonds is shown in orange. Loop 2 residues that are observed are shown in light green; it must be noted that the conformation of loop 2 is different from that of (A), resulting in different orientations for the residues involved in ligand binding. Ligand residues 31-41 having electron density are highlighted in dark green and the backbone is shown as a dark green ribbon. (E), (F) NMR structures of the ECD1-CRF-R1 complexed with αhcCRF. The backbone ribbon of the ECD1 along with the highly conserved residues including the disulphide bonds is shown in cyan. Side chains of loop 2 residues are shown in light green. The conformation of loop 2 is very close to that of (A) and is different from that of (C). The side chains of F 71 , Y 73 and R 76 were assigned and hence their interactions with the ligand could be observed. 
